methotrexate Articles
B-MS discusses two-year Orencia trial data
3 July 2006
Abbott's Humira gets EU OK for AS
19 June 2006
B-MS's Orencia performs well in trials
15 May 2006
Strong RA data for Abbott's Humira + MTX
15 May 2006
Japan to discuss pediatric drug use
10 April 2006
Genentech/Biogen Idec submit Rituxan sBLA
3 April 2006
Spectrum acquires Targent's LFA assets
27 March 2006
Erbitux approved by FDA in SCCHN
13 March 2006
Rigel's RA drug sees good Ph I data
27 February 2006
Chelsea Thera closed $21.5M placement
20 February 2006
Protherics swings to loss in fiscal first half
19 December 2005
A review of the 2005 meeting of the American College of Rheumatology
12 December 2005
Arakis/Sosei's RA drug goes into Ph IIb
12 September 2005
B-MS' Abatacept inhibits RA damage
20 June 2005
Abbott's Humira/MTX: good long-term outcome
20 June 2005
Strong data for Roche/Genentech/Biogen Idec's MabThera
25 April 2005
Arakis' antirheumatic passes Phase IIa
18 April 2005
UPDATE: Roche's Rituxan shows improvement in RA
18 April 2005
Allos starts Ph I trial of PDX in NSCLC
31 January 2005
Abbott submits Humira filings for RA
10 January 2005
Abbott's Humira filed for new use in USA and EU
10 January 2005
Protherics sees profit for six-month period
20 December 2004
STADA extends voucher program for Rheumatrex
13 December 2004
Positive new data on Centocor's Remicade
15 November 2004
Raptiva launched in UK for psoriasis
8 November 2004
New data for Amgen/Wyeth's Enbrel at ACR
25 October 2004
S-P's Remicade: EU OK for psoriatic arthritis
25 October 2004
Serono's Raptiva Oked for psoriasis in EU
4 October 2004
Protherics reviews early stage portfolio
4 October 2004
Positive new data for UCB's CDP-870 in RA
27 September 2004
FDA OKs expanded use of Abbott's Humira
16 August 2004
APP buys Bigmar's European facility and products
2 August 2004
Tokyo pharma stocks - week to july 26
2 August 2004
Lehman Bros forecast peak sales of Raptiva at $250M
28 June 2004
S-P's Remicade cleared in EU for early RA
28 June 2004
Remicade reverses joint destruction in RA
12 April 2004
Allos Therapeutics to raise $75M
15 March 2004
Antegren to be studied in RA patients
9 February 2004
First named-patient sales of Protherics' Voraxaze
2 February 2004
Enbrel cleared for new use in EU
26 January 2004
Abbott Labs' Humira marks first successful year
5 January 2004
Positive Ph II data for Roche/Chugai's MRA
10 November 2003
Abbott files for new Humira indication
13 October 2003
Introgen's Advexin on FDA fast-track
29 September 2003
MedImmune initiates two Ph II trials for Vitaxin
15 September 2003
FDA clears expanded use of Enbrel
11 August 2003
Abbott moves closer to EU Humira approval
2 June 2003
Protherics acquires Enact and makes L3M placing
12 May 2003
Enact's Voraxaze gets orphan designation
17 February 2003
Enact's Voraxaze backed for orphan status
6 January 2003
Genmab losses rocket in first-half 2002
22 July 2002
Serono drops drug for rheumatoid arthritis
3 June 2002
UK NICE OKs Remicade for some Crohn's cases
13 May 2002
Remicade gains FDA priority for CD
8 April 2002
Roche's Xeloda in Ph III as first-line agent
11 March 2002
Enbrel also active in psoriasis, says study
4 March 2002
Genmab gets fast-track for HuMax-CD4
25 February 2002
Immunex' Enbrel cleared for psoriatic arthritis.
21 January 2002
Alexion completes Phase I study of 5G1.1
7 January 2002
Alexion completes Phase I study of 5G1.1
24 December 2001
New safety data on Amgen's Kineret bode well for its use in RA
14 November 2001
Immunex' Enbrel filed for psoriatic arthritis
17 July 2001
EU extends Remicade indications
7 February 2001
Enbrel approved in Canada
14 December 2000
Aventis' Arava "enhances treatment"
30 October 2000
Immunex' Enbrel shows long-term use
30 October 2000
Amgen reveals Ph II anakinra results
30 October 2000
Remicade gains broader label for RA
26 October 2000
Schering-Plough sees desloratadine backing
12 October 2000
IDEC begins PhII rheumatoid arthritis trial
10 August 2000
Remicade OKed in EU for rheumatoid arthritis
5 July 2000
Remicade approved for RA in the UK
29 June 2000
Aventis' Arava shows functional benefits
26 June 2000
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
